Cidara Therapeutics's revenue for the
three
months ended in Dec. 2023 was $17.58 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $63.91 Mil.
Cidara Therapeutics's Revenue per Share for the
three
months ended in Dec. 2023 was $3.88.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $13.53.
Warning Sign:
Cidara Therapeutics Inc revenue per share is in decline over the past 12 months.
During the past 11 years, Cidara Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 36.00% per year. The lowest was 9.70% per year. And the median was 22.85% per year.
Cidara Therapeutics Revenue Historical Data
The historical data trend for Cidara Therapeutics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cidara Therapeutics's Revenue
For the Biotechnology subindustry, Cidara Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cidara Therapeutics's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Cidara Therapeutics's Revenue falls into.
Cidara Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $63.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Cidara Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Cidara Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cidara Therapeutics (Cidara Therapeutics) Business Description
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDTX has been successfully added to your 